` 688016 (Shanghai MicroPort Endovascular MedTech Group Co Ltd) vs Shanghai Composite Comparison - Alpha Spread

688016
vs
Shanghai Composite

Over the past 12 months, has underperformed Shanghai Composite, delivering a return of -42% compared to the Shanghai Composite's 12% growth.

Stocks Performance
688016 vs Shanghai Composite

Loading
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
688016 vs Shanghai Composite

Loading
688016
Shanghai Composite
Difference

Performance By Year
688016 vs Shanghai Composite

Loading
688016
Shanghai Composite
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Shanghai MicroPort Endovascular MedTech Group Co Ltd vs Peers

Shanghai Composite
688016
7741
ALC
COLO B
ALGN
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Shanghai MicroPort Endovascular MedTech Group Co Ltd
Glance View

Market Cap
13B CNY
Industry
Health Care

Shanghai MicroPort Endovascular MedTech Group Co Ltd stands as a testament to China's burgeoning capabilities in the medtech landscape. The company was born from a vision to develop innovative solutions for treating cardiovascular diseases, which are among the leading causes of mortality worldwide. MicroPort Endovascular crafts specialized medical devices aimed at minimally invasive therapies, particularly in the vascular intervention domain. They produce stents, embolization coils, and vascular grafts—tools essential for intricate procedures like repairing damaged blood vessels or preventing life-threatening aneurysms. By aligning with cutting-edge technological advancements and rigorous clinical testing, MicroPort Endovascular has cemented its reputation as a trusted partner for medical professionals seeking reliable, effective, and technologically advanced instruments. MicroPort Endovascular’s revenue model is intrinsically linked to the global demand for cardiovascular solutions. With increasing incidences of cardiovascular diseases, partly due to lifestyle shifts and an aging population, the firm strategically positions itself in both domestic and international markets to capitalize on this demand. Their business operations span research and development, manufacturing, and distribution, allowing them to maintain control over quality and innovation while optimizing costs. Revenue flows from direct sales to hospitals and healthcare providers, as well as partnerships with distributors, ensuring widespread market penetration. Their continuous investment in R&D not only drives the introduction of new products but also enhances existing ones, thereby maintaining a competitive edge in a field where innovation is tantamount to success.

Intrinsic Value
176.77 CNY
Undervaluation 40%
Intrinsic Value
Price
Back to Top